Amgen Says FDA Approves Avsola for Same Indications as Remicade

Date : 12/06/2019 @ 8:23PM
Source : Dow Jones News
Stock : Amgen Inc (AMGN)
Quote : 237.6  -3.89 (-1.61%) @ 4:59AM
After Hours
Last Trade
Last $ 237.18 ▼ -0.42 (-0.18%)

Amgen Says FDA Approves Avsola for Same Indications as Remicade

Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Amgen Charts.
   By Stephen Nakrosis 

Amgen Inc. (AMGN) on Friday said the U.S. Food and Drug Administration approved its Avsola for all approved indications of Remicade.

Amgen said the indications include treatment of rheumatoid arthritis, Crohn's Disease, ulcerative colitis and chronic severe plaque psoriasis, among others.

The approval for Avsola, or infliximab-axxq, is the fourth from the FDA for a product from Amgen's biosimilars portfolio, the company said.

Avsola "was proven to be highly similar to Remicade with no clinically meaningful differences," Amgen said.

Avsola is currently not available commercially.

Remicade is marketed by Janssen Biotech, Inc., a Johnson & Johnson (JNJ) company.


--Write to Stephen Nakrosis at


(END) Dow Jones Newswires

December 06, 2019 15:08 ET (20:08 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.